Taiwan Extends Cosmetic GMP Requirements to Nearly All Manufacturing Sites

On May 27, 2026, the Taiwan Food and Drug Administration (TFDA) announced the final implementation of Good Manufacturing Practice (GMP) requirements for cosmetic manufacturing sites. Following amendments to the Cosmetic Hygiene and Safety Act, these standards — modeled on the international ISO 22716 guidelines — now apply to nearly all cosmetic production facilities in Taiwan as of July 1, 2026.

This milestone concludes a five-year transition period, establishing a harmonized quality standard across the industry, with the sole exception of solid handmade soap manufacturers that are not required to register as factories.

The rollout was executed in three risk-based phases.

• Phase 1 (Effective July 1, 2024): Special-purpose cosmetics (e.g., sunscreens, hair dyes, antiperspirants, teeth whiteners).
• Phase 2 (Effective July 1, 2025): Products for sensitive use (e.g., baby cosmetics, eye/lip products, mouthwash).
• Phase 3 (Effective July 1, 2026): All remaining general cosmetic manufacturing sites.

Aligning with International Standards

The TFDA’s GMP framework shifts the industry focus from simple finished-product testing to comprehensive quality management throughout the entire production lifecycle. Compliant manufacturers must align their operations with their Product Information File (PIF), with documented procedures covering activities from raw material weighing, charging and mixing through filling, packaging, finished product testing, and recordkeeping.

To ensure consistent product quality and minimize risk, manufacturers must maintain robust controls over:

• Personnel training and responsibilities
• Premises and facility management
• Equipment qualification and maintenance
• Raw materials and packaging materials
• Manufacturing operations
• Quality control and testing
• Documentation, recordkeeping, and traceability

Implications for International Brands

While these regulations apply to manufacturing sites within Taiwan, the impact extends to any international brand that owns, operates, or contracts with Taiwanese facilities.

Organizations already aligned with ISO 22716 may find their existing systems largely satisfy the TFDA’s requirements. However, a facility-specific review is essential to ensure local regulatory nuances are met. For manufacturers with less mature quality systems, immediate efforts should focus on aligning documentation, personnel training, and process controls with the TFDA’s expectations.

Ensuring Ongoing Compliance and Audit Readiness

With the mandatory implementation deadline now in effect, the TFDA is expected to shift its focus toward active industry oversight, including site inspections and compliance verification. Manufacturers should move beyond initial implementation and focus on "audit-ready" operational standards.

To maintain compliance and mitigate regulatory risk, companies should prioritize the following:

• Implement Internal Audits: Establish a recurring self-inspection schedule to identify and rectify potential drifts in process control or documentation before official inspections occur.
• Monitor Regulatory Updates: Proactively track any new TFDA guidance or circulars regarding ISO 22716 compliance, as regulatory interpretations can evolve.
• Strengthen Change Control: Ensure that any modifications to facilities, equipment, or manufacturing processes are formally documented and evaluated for their impact on GMP compliance.
• Continuous Personnel Training: Regularly refresh staff training on current SOPs to ensure that quality culture is maintained as a standard operating practice, rather than a one-time effort.
• Maintain Audit Trails: Consolidate records and supporting documentation into a structured, easily retrievable format, ensuring that full traceability is available for any product batch produced post-deadline.

Final Thoughts

With the TFDA intensifying its focus on industry oversight, maintaining a robust GMP framework is key to safeguarding your brand’s market access and operational continuity. Moving beyond basic compliance to achieve "audit-ready" status is the most effective way to mitigate risk, insulate your supply chain from disruptions, and demonstrate an unwavering commitment to product safety.

However, translating these high-level standards into daily operational excellence can be complex. This is where Cisema bridges the gap. We guide cosmetic brands through the intricacies of the evolving regulatory landscape in Taiwan and the wider Asia-Pacific region, providing end-to-end support — from comprehensive GMP gap assessments to the design of tailored compliance strategies — that keeps your operations seamless and secure.

If your company manufactures products in Taiwan or is planning to register cosmetics in the market, contact Cisema today to assess your regulatory needs.

Further Information

• Explore Cisema’s services for Cosmetics Registration in Taiwan.

References

• Cosmetic Hygiene and Safety Act
• Cosmetics Manufacturing Sites Fully Implement GMP

‍